Interferon alpha2a and vindesine in the treatment of advanced malignant melanoma
- 31 March 1992
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (2-3) , 438-441
- https://doi.org/10.1016/s0959-8049(05)80071-1
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Interferon plus dacarbazine in advanced malignant melanoma: a phase I–II studyEuropean Journal of Cancer and Clinical Oncology, 1991
- Phase II Trial of Recombinant Leukocyte A Interferon (IFN-α2A) Plus l,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU) and the Combination Cimetidine with BCNU in Patients with Disseminated Malignant MelanomaAmerican Journal of Clinical Oncology, 1991
- Phase II Study of Interferon α-2a and Dacarbazine in Advanced MelanomaAmerican Journal of Clinical Oncology, 1990
- Phase II Assessment of Recombinant Leukocyte A Interferon with Difluoromethylornithine in Disseminated Malignant MelanomaAmerican Journal of Clinical Oncology, 1990
- Interleukin-2 in Combination with Interferon-Alpha in Disseminated Malignant Melanoma and Advanced Renal Cell CarcinomaOncology Research and Treatment, 1990
- Dacarbazine versus dacarbazine-vindesine in disseminated malignant melanoma: A randomized phase II studyMedical Oncology and Tumor Pharmacotherapy, 1989
- Intralesional interferon-alpha therapy in advanced malignant melanomaCancer, 1988
- Role of recombinant interferon alpha2 and cimetidine in patients with advanced malignant melanomaZeitschrift für Krebsforschung und Klinische Onkologie, 1988
- Treatment of metastatic malignant melanoma with recombinant interferon alfa-2bInvestigational New Drugs, 1987
- Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dticInternational Journal of Cancer, 1987